Comparable long-term mortality risk associated with individual sulfonylureas in diabetes patients with heart failure

Diabetes Research and Clinical Practice

Volumn 94, Issue 1, 2011, Pages 119-125

  Andersson, Charlotte ^a   Gislason, Gunnar H ^a   Jørgensen, Casper H ^a   Hansen, Peter R ^a   Vaag, Allan ^b   Sørensen, Rikke ^a   Mérie, Charlotte ^a   Olesen, Jonas B ^a   Weeke, Peter ^a   Schmiegelow, Michelle ^a   Norgaard, Mette L ^a   Køber, Lars ^c   Torp Pedersen, Christian ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b STENO DIABETES CENTER   (Denmark)

^c Rigshospitalet   (Denmark)

Author keywords

Heart failure; Long term prognosis; Sulfonylureas

Indexed keywords

GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; TOLBUTAMIDE;

ADULT; AGED; ARTICLE; CLINICAL OBSERVATION; CONTROLLED STUDY; DENMARK; DIFFERENTIAL DIAGNOSIS; DRUG SPECIFICITY; FEMALE; HEART FAILURE; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS; PROGNOSIS; REGISTER;

AGED; AGED, 80 AND OVER; DIABETES MELLITUS; FEMALE; GLIPIZIDE; GLYBURIDE; HEART FAILURE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; SULFONYLUREA COMPOUNDS; TOLBUTAMIDE;

EID: 80054945652     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2011.07.011     Document Type: Article

References (31)

1. Jorgensen C.H., Gislason G.H., Andersson C., Ahlehoff O., Charlot M., Schramm T.K., et al. Effects of oral glucose-lowering drugs on long term outcomes in patients with diabetes mellitus following myocardial infarction not treated with emergent percutaneous coronary intervention - a retrospective nationwide cohort study. Cardiovasc Diabetol 2010, 9:54.
2. Jorgensen CH, Gislason GH, Bretler D, Sorensen R, Norgaard ML, Hansen ML, et al. Glyburide increases risk in patients with diabetes mellitus after emergent percutaneous intervention for myocardial infarction - a nationwide study. Int J Cardiol, Available online 24 Aug 2010. In press.
3. Gribble F.M., Reimann F. Sulphonylurea action revisited: the post-cloning era. Diabetologia 2003, 46(7):875-891.
4. Gumina R.J., O'Cochlain D.F., Kurtz C.E., Bast P., Pucar D., Mishra P., et al. KATP channel knockout worsens myocardial calcium stress load in vivo and impairs recovery in stunned heart. Am J Physiol Heart Circ Physiol 2007, 292(4):H1706-H1713.
5. Vanden Hoek T., Becker L.B., Shao Z.H., Li C.Q., Schumacker P.T. Preconditioning in cardiomyocytes protects by attenuating oxidant stress at reperfusion. Circ Res 2000, 86(5):541-548.
6. Yamada S., Kane G.C., Behfar A., Liu X.K., Dyer R.B., Faustino R.S., et al. Protection conferred by myocardial ATP-sensitive K+ channels in pressure overload-induced congestive heart failure revealed in KCNJ11 Kir6.2-null mutant. J Physiol 2006, 577(Pt. 3):1053-1065.
7. Lefer D.J., Nichols C.G., Coetzee W.A. Sulfonylurea receptor 1 subunits of ATP-sensitive potassium channels and myocardial ischemia/reperfusion injury. Trends Cardiovasc Med 2009, 19(2):61-67.
8. Gribble F.M., Reimann F. Differential selectivity of insulin secretagogues: mechanisms, clinical implications, and drug interactions. J Diabetes Complications 2003, 17(Suppl. 2):11-15.
9. Gribble F.M., Tucker S.J., Seino S., Ashcroft F.M. Tissue specificity of sulfonylureas: studies on cloned cardiac and beta-cell K(ATP) channels. Diabetes 1998, 47(9):1412-1418.
10. Pantalone K.M., Kattan M.W., Yu C., Wells B.J., Arrigain S., Jain A., et al. The risk of overall mortality in patients with type 2 diabetes receiving glipizide, glyburide, or glimepiride monotherapy: a retrospective analysis. Diabetes Care 2010, 33(6):1224-1229.
11. Fosbol E.L., Gislason G.H., Jacobsen S., Folke F., Hansen M.L., Schramm T.K., et al. Risk of myocardial infarction and death associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) among healthy individuals: a nationwide cohort study. Clin Pharmacol Ther 2009, 85(2):190-197.
12. Gislason G.H., Rasmussen J.N., Abildstrom S.Z., Gadsboll N., Buch P., Friberg J., et al. Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction. Eur Heart J 2006, 27(10):1153-1158.
13. Sorensen R., Hansen M.L., Abildstrom S.Z., Hvelplund A., Andersson C., Jorgensen C., et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet 2009, 374(9706):1967-1974.
14. Gaist D., Sorensen H.T., Hallas J. The Danish prescription registries. Dan Med Bull 1997, 44(4):445-448.
15. Gislason G.H., Rasmussen J.N., Abildstrom S.Z., Schramm T.K., Hansen M.L., Buch P., et al. Persistent use of evidence-based pharmacotherapy in heart failure is associated with improved outcomes. Circulation 2007, 116(7):737-744.
16. Charlson M.E., Pompei P., Ales K.L., MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40(5):373-383.
17. Eshaghian S., Horwich T.B., Fonarow G.C. Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol 2006, 97(12):1759-1764.
18. Fisher L.D., Lin D.Y. Time-dependent covariates in the Cox proportional-hazards regression model. Annu Rev Public Health 1999, 20:145-157.
19. Garratt K.N., Brady P.A., Hassinger N.L., Grill D.E., Terzic A., Holmes D.R. Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. J Am Coll Cardiol 1999, 33(1):119-124.
20. Klepzig H., Kober G., Matter C., Luus H., Schneider H., Boedeker K.H., et al. Sulfonylureas and ischaemic preconditioning; a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide. Eur Heart J 1999, 20(6):439-446.
21. Kane G.C., Liu X.K., Yamada S., Olson T.M., Terzic A. Cardiac KATP channels in health and disease. J Mol Cell Cardiol 2005, 38(6):937-943.
22. Evans J.M., Ogston S.A., Reimann F., Gribble F.M., Morris A.D., Pearson E.R. No differences in mortality between users of pancreatic-specific and non-pancreatic-specific sulphonylureas: a cohort analysis. Diabetes Obes Metab 2008, 10(4):350-352.
23. Torp-Pedersen C., Kober L., Elming H., Burchart H. Classification of sudden and arrhythmic death. Pacing Clin Electrophysiol 1997, 20(10 Pt 2):2545-2552.
24. Neubauer S. The failing heart - an engine out of fuel. N Engl J Med 2007, 356(11):1140-1151.
25. Hodgson D.M., Zingman L.V., Kane G.C., Perez-Terzic C., Bienengraeber M., Ozcan C., et al. Cellular remodeling in heart failure disrupts K(ATP) channel-dependent stress tolerance. EMBO J 2003, 22(8):1732-1742.
26. Kumler T., Gislason G.H., Kirk V., Bay M., Nielsen O.W., Kober L., et al. Accuracy of a heart failure diagnosis in administrative registers. Eur J Heart Fail 2008, 10(7):658-660.
27. Andersson C., Olesen J.B., Hansen P.R., Weeke P., Norgaard M.L., Jorgensen C.H., et al. Metformin treatment is associated with a low risk of mortality in diabetic patients with heart failure: a retrospective nationwide cohort study. Diabetologia 2010, 53(12):2546-2553.
28. Andersson C., Sogaard P., Hoffmann S., Hansen P.R., Vaag A., Major-Pedersen A., et al. Metformin is associated with improved left ventricular diastolic function measured by tissue Doppler imaging in patients with diabetes. Eur J Endocrinol 2010, 163(4):593-599.
29. Eurich D.T., Majumdar S.R., McAlister F.A., Tsuyuki R.T., Johnson J.A. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care 2005, 28(10):2345-2351.
30. Masoudi F.A., Inzucchi S.E., Wang Y., Havranek E.P., Foody J.M., Krumholz H.M. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation 2005, 111(5):583-590.
31. Nathan D.M., Buse J.B., Davidson M.B., Ferrannini E., Holman R.R., Sherwin R., et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009, 32(1):193-203.